Last reviewed · How we verify

Arm 2. Iodophor/CHG Decolonization

Harvard Pilgrim Health Care · FDA-approved active Small molecule

Iodophor and chlorhexidine gluconate (CHG) work together to reduce pathogenic bacteria colonization on skin through antimicrobial activity.

Iodophor and chlorhexidine gluconate (CHG) work together to reduce pathogenic bacteria colonization on skin through antimicrobial activity. Used for Skin decolonization to reduce surgical site infections, Reduction of pathogenic skin colonization in hospitalized patients.

At a glance

Generic nameArm 2. Iodophor/CHG Decolonization
SponsorHarvard Pilgrim Health Care
Drug classTopical antimicrobial/antiseptic combination
ModalitySmall molecule
Therapeutic areaInfection Prevention
PhaseFDA-approved

Mechanism of action

Iodophor is an iodine-based antiseptic that disrupts bacterial cell membranes and protein synthesis, while CHG is a broad-spectrum antimicrobial that damages bacterial cell walls and membranes. Together, they are used for skin decolonization to reduce the burden of pathogenic organisms (particularly Staphylococcus aureus) on the skin surface before surgical procedures or in hospitalized patients at risk for infection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: